Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph N
The main objective of this study is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves overall survival rates compared to standard therapy alone in women with cervical cancer with paraaortic lymph node involvement. Wom
| Condition(s) | Cervical Cancer TNM Staging Regional Lymph Nodes (N) |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | The main objective of this study is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves overall survival rates compared to standard therapy alone in women with cervical cancer with paraaortic lymph node involvement. Women in the experimental arm will receive neoadjuvant chemotherapy with carboplatin and paclitaxel every 21 days during 3 cycles followed by standard therapy with extended field external radiation therapy and concomitant chemotherapy. Women in the control arm will receive standard therapy with extended field external radiation therapy and concomitant chemotherapy. 310 patients will be recruited during 4.5 years, with 3 years of follow up period. |
| Who can participate | Inclusion Criteria: * Women with histologically proven invasive carcinoma of the uterine cervix and para aortic lymphadenopathy determined by either a positive positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography or if negative positron emission tomography computed tomography based on histological examination of paraaortic lymph node dissection. * Performance status Eastern Cooperative Oncology Group 0-2 * Stage International Federation of Gynecology and Obstetrics IB1 to IVA at diagnosis with para-aortic lymph node involvement * Adenocarcinoma or squamous cell carcinoma or adenosquamous carcinoma * Adequate renal function (creatinine clearance ≥60 mL/min) * Adequate hepatic function (bilirubin \<1.5 times normal and Serum Glutamo |
| Ages | 18 Years |
| Sex | Female |
| Lead sponsor | University Hospital, Toulouse |
| Locations | Bordeaux, France; Clermont-Ferrand, France; Créteil, France; Marseille, France; Pierre-Bénite, France; Poitiers, France (+5 more sites) |
| Start date | 2020-07-17 |
| NCT ID | NCT03534713 |
| Official listing | https://clinicaltrials.gov/study/NCT03534713 |